12 Peptides Removed from FDA Category 2: What Changed and What's Next

FDA sorts bulk drug substances nominated for 503A compounding into three categories. Category 1 holds substances under evaluation. Category 2 holds substances that raise significant safety risks. Category 3 holds substances nominated without adequate support. The system is older than this peptide list: FDA added domperidone to Category 2 on October 27, 2015 and cesium chloride on July 30, 2018.

Category 2 was the restriction: substances FDA flagged for "significant safety risks" that pharmacies could not compound during review.

The effect was immediate. Compounding pharmacies producing BPC-157, TB-500, and other peptides for patients with active prescriptions stopped overnight. Practitioners scrambled for alternatives. The 12 peptides on this list were among the most commonly compounded peptides in the country.

The nominators then withdrew all 12. FDA's Category 2 page (current as of April 22, 2026) lists them under "Bulk drug substances nominated but withdrawn." FDA's Pharmacy Compounding Advisory Committee (PCAC) met on July 23 and 24, 2026 to discuss 7 of them.

Four peptides in this group target tissue repair through different mechanisms.

A 2025 systematic review screened 544 papers on BPC-157 (PMID 40756949). Thirty-six met inclusion criteria; thirty-five were animal studies. This 15-amino-acid peptide from human gastric juice promotes repair through angiogenesis and nitric oxide modulation. Community evidence fills the gap. Tens of thousands of user reports across Reddit and practitioner networks describe accelerated healing within 2 to 4 weeks. 212 PubMed papers. Safety grade: C.

The first Phase 1 human trial for TB-500 confirmed safety in healthy volunteers (PMID 34346165). This seven-amino-acid fragment of thymosin beta-4 promotes cell migration through actin cytoskeleton remodeling. 172 PubMed citations. Community protocols commonly pair it with BPC-157 for injury recovery. Safety grade: C.

GHK-Cu switches over 4,000 genes toward a repair state (PMID 29986520). Plasma levels of this copper tripeptide drop from 200 ng/mL at age 20 to roughly 80 ng/mL by age 60. Available as both injectable and topical formulations. Only injectable GHK-Cu was on Category 2; non-injectable GHK-Cu is back on FDA's Category 1 list (under evaluation) as of May 14, 2026. 162 PubMed papers. Safety grade: A, the highest of any peptide in this group.

KPV enters intestinal cells through PepT1 transporters, making oral dosing a viable route (PMID 18061177). This tripeptide from alpha-MSH shows promising preclinical data for intestinal inflammation. Human studies remain limited. 15 PubMed papers. Safety grade: C.

These three span different pathways. Each has at least one notable human or human-cell study.

A 2025 paper independently confirmed Epithalon's telomere elongation effect in human cell lines for the first time outside Khavinson's lab (PMID 40908429). This synthetic tetrapeptide activates telomerase, the enzyme that adds TTAGGG repeats to chromosome ends. 140 PubMed citations. Safety grade: B.

Skeletal muscle produces 12 times more MOTS-c during exercise than at rest (PMID 33473109). This 16-amino-acid mitochondrial peptide regulates metabolic homeostasis through AMPK activation. Lee's group first described its effects on obesity and insulin resistance in 2015 (PMID 25738459). 100 PubMed papers. Safety grade: B.

The 12th peptide is PEG-MGF, not MK-677. FDA's Category 2 page still lists ibutamoren mesylate (MK-677) in Category 2, for 503A since September 29, 2023. PEG-MGF is a PEGylated form of mechano growth factor, the E-peptide muscle releases after mechanical loading. Native MGF clears in about 5 to 7 minutes; the PEG chain pushes the estimated half-life to 48 to 72 hours. McKoy and colleagues confirmed MGF's E-peptide activates human muscle progenitor cells (PMID 21354439). No human trial has tested PEG-MGF itself. 4 PubMed papers. Safety grade: C.

This group ranges from the well-studied to the controversial.

Semax has 226 PubMed citations and prescription approval in Russia. A single injection at 50 mcg/kg produced a 3-fold BDNF increase in the rat hippocampus (PMID 16996037). It's one of the better-studied nootropic peptides. Safety grade: B. Administered as a nasal spray.

Two key papers supporting Dihexa were retracted in April 2025 (J Pharmacol Exp Ther retraction notices, PMIDs 40312092 and 40312093). Athira Pharmaceuticals settled a related False Claims Act case for $4 million. The remaining evidence points to HGF/c-Met pathway activation for cognitive effects. 60 PubMed papers. Safety grade: C. Approach this one with caution.

The largest controlled human study on DSIP enrolled 14 chronic insomniacs in a 1992 double-blind trial (PMID 1299794). Results showed improved delta-wave sleep without REM suppression. Under-studied despite 150 PubMed citations. Safety grade: B.

A Phase 2 dose-finding trial of LL-37 in 34 patients with venous leg ulcers found the 0.5 mg/mL arm healed at a rate 6 times higher than placebo (P=0.003; PMID 25041740). A larger 148-patient randomized trial did not confirm a significant healing benefit (PMID 34687253). Over 1,000 PubMed papers make this the most-published peptide on the list. Safety grade: B.

Melanotan II activates five melanocortin receptors, producing UV-free tanning, libido effects, and appetite suppression. Dorr's Phase 1 trial confirmed pharmacological activity in 1996 (PMID 8637402). Five published melanoma cases and one renal infarction event sit in the literature. Over 500 Reddit threads document consistent tanning results. Safety grade: C.

The Pharmacy Compounding Advisory Committee (PCAC) is an independent panel of pharmacists, physicians, and scientists that advises the FDA. It met on July 23, 2026 on BPC-157, KPV, TB-500 and MOTS-c, and on July 24 on emideltide (DSIP), epitalon and Semax. Each vote asked whether FDA should place the substance on the 503A bulks list.

As of October 6, 2026, FDA's meeting page held the agenda, questions, roster and briefing documents, but no minutes or vote results. Vote counts in press reports are not FDA figures. FDA says it intends to consult PCAC on GHK-Cu before the end of February 2027, and a law-firm summary of the July meeting reports the same timing for Dihexa, LL-37, PEG-MGF and Melanotan II.

Removal from Category 2 is not the same as approval for compounding. The committee makes recommendations. The FDA makes the final call, and adding a substance to the 503A bulks list takes an FDA rule. A Federal Register search on October 6, 2026 found no proposed or final FDA rule on the 503A list since April 15, 2026.

Pharmaceutical companies may also file new drug applications (NDAs) for specific peptides during this period. If a peptide receives NDA approval, it would move from compounding to standard prescribing with a brand-name product.

Compounding pharmacies still cannot compound 11 of these peptides, or injectable GHK-Cu. Leaving Category 2 did not put any of them on the 503A bulks list; that takes an FDA rule. Non-injectable GHK-Cu sits elsewhere: it is back on FDA's Category 1 list (under evaluation) as of May 14, 2026, after one nominator kept that part of its nomination.

Peptides sold as research chemicals sit in a regulatory gray area. Their quality, purity, and sterility vary, and none is made for human use.

Three things to watch. First, FDA's minutes from the July meeting and a PCAC date for the remaining 5. Second, any proposed FDA rule on the 503A bulks list. Third, state-level pharmacy board guidance on compounding rules during the review period.

Check individual peptide pages on Peptide Schedule for detailed dosing, safety, and evidence profiles. Use the Peptide Calculator to plan doses and the Protocol Builder to create a full protocol with calendar sync. Run the Interaction Checker before combining any peptides. For the current FDA and compounding status of each of these peptides, with the FDA documents behind it, see the peptide regulatory tracker.

This content is for educational purposes only. Consult a healthcare provider before using any peptide.